Disc Medicine

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematologic diseases. The company is dedicated to turning scientific discoveries into therapies that have a meaningful impact on patients' lives, alleviating suffering, and enabling vibrant lives through innovative approaches in biology.

Products & Services

Bitopertin:A potential treatment for erythropoietic protoporphyria (EPP), with plans to submit an NDA under an accelerated approval pathway in October 2025.

DISC-0974:A therapeutic candidate in development, specifics not detailed in the content.

Specialties

Hematologic Diseases Novel Treatments for Blood Disorders Drug Discovery and Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 225000000 MR: - FA: $225 million FAN: 225000000	D: 2025-10-21 FD: 2025-10-21	-
2	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 220000000 MR: - FA: $220.0 million FAN: 220000000	D: 2025-10-20 FD: 2025-10-20	5 investors
3	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 225500000 MR: - FA: $225.5 million FAN: 225500000	D: 2025-01-22 FD: 2025-01-22	8 investors
4	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2025-01-21 FD: 2025-01-21	4 investors
5	RT: Debt Financing T: - FT: Debt Financing	A: 200000000 MR: - FA: Up to $200 million FAN: 200000000	D: 2024-11-08 FD: 2024-11-08	1 investors
6	RT: Equity T: - FT: Equity	A: 178000000 MR: - FA: approximately $178.0 million FAN: 178000000	D: 2024-06-14 FD: 2024-06-14	11 investors
7	RT: Public Offering T: - FT: Public Offering	A: 157800000 MR: - FA: approximately $157.8 million FAN: 157800000	D: 2023-06-22 FD: 2023-06-22	5 investors
8	RT: Public Offering T: - FT: Public Offering	A: 137200000 MR: - FA: $137.2 million FAN: 137200000	D: 2023-06-13 FD: 2023-06-13	5 investors
9	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2023-06-12 FD: 2023-06-12	5 investors
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 62500000 MR: - FA: 62.5 million FAN: 62500000	D: 2023-02-14 FD: 2023-02-14	3 investors

Public Offering Latest

2025-10-21

$225.0M

Public Offering of Common Stock and Pre-Funded Warrants 2025-10-20

$220.0M

Public Offering of Common Stock and Pre-Funded Warrants 2025-01-22

$225.5M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Quisel

Chief Executive Officer

J

Jean Franchi

Chief Financial Officer

J

Jonathan Yu

Chief Operating Officer

W

Will Savage

Chief Medical Officer

P

Pamela Stephenson

Chief Commercial Officer

S

Steve Caffé

Chief Regulatory Officer

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Disc Medicine Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised